Blar i Bergen Open Research Archive på forfatter "Dalgard, Olav"

Viser treff 1-4 av 4

    • Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID‑19 (Bari‑SolidAct): a randomised, double‑blind, placebo‑controlled phase 3 trial 

      Trøseid, Marius; Arribas, José R.; Assoumou, Lambert; Holten, Aleksander Rygh; Poissy, Julien; Terzic, Vida; Mazzaferri, Fulvia; Baño, Jesús Rodríguez; Eustace, Joe; Hites, Maya; Joannidis, Michael; Paiva, José-Artur; Reuter, Jean; Püntmann, Isabel; Patrick-Brown, Thale Dawn; Westerheim, Elin; Nezvalova-Henriksen, Katerina; Beniguel, Lydie; Dahl, Tuva Børresdatter; Bouscambert, Maude; Halanova, Monika; Péterfi, Zoltán; Tsiodras, Sotirios; Rezek, Michael; Briel, Matthias; Ünal, Serhat; Schlegel, Martin; Ader, Florence; Lacombe, Karine; Amdal, Cecilie Delphin; Rodrigues, Serge; Tonby, Kristian; Gaudet, Alexandre; Heggelund, Lars; Mootien, Joy; Johannessen, Asgeir; Møller, Jannicke Horjen; Pollan, Beatriz Diaz; Tveita, Anders Aune; Kildal, Anders Benjamin; Richard, Jean-Christophe; Dalgard, Olav; Simensen, Victoria Charlotte; Baldé, Aliou; de Gastines, Lucie; del Álamo, Marta; Aydin, Burç; Lund-Johansen, Fridtjof; Trabaud, Mary-Anne; Diallo, Alpha; Halvorsen, Bente; Røttingen, John-Arne; Tacconelli, Evelina; Yazdanpanah, Yazdan; Olsen, Inge Christoffer; Costagliola, Dominique; Study Group, EU-SolidAct (Journal article; Peer reviewed, 2023)
      Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct ...

    • Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations 

      Chalabianloo, Fatemeh; Høiseth, Gudrun; Vold, Jørn Henrik; Johansson, Kjell Arne; Kringen, Marianne K.; Dalgard, Olav; Ohldieck, Christian; Druckrey-Fiskaaen, Karl Trygve; Aas, Christer Frode; Løberg, Else-Marie; Bramness, Jørgen Gustav; Fadnes, Lars T. (Journal article; Peer reviewed, 2023)
      Background: There is limited knowledge on the causes of large variations in serum methadone concentrations and dose requirements. Objectives: We investigated the impact of the degree of liver fibrosis on dose-adjusted ...

    • Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV) 

      Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Leiva, Rafael Alexander Mo; Ohldieck, Christian; Chalabianloo, Fatemeh; Skurtveit, Svetlana Ondrasova; Lygren, Ole Jørgen; Dalgard, Olav; Vickerman, Peter; Midgard, Håvard; Løberg, Else-Marie; Johansson, Kjell Arne (Journal article; Peer reviewed, 2021)
      Background The standard pathways of testing and treatment for hepatitis C virus (HCV) infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this study was to evaluate the ...

    • Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV) 

      Fadnes, Lars T.; Aas, Christer Frode; Vold, Jørn Henrik; Ohldieck, Christian; Leiva, Rafael Alexander Mo; Chalabianloo, Fatemeh; Skurtveit, Svetlana; Lygren, Ole Jørgen; Dalgard, Olav; Vickerman, Peter; Midgard, Håvard; Løberg, Else-Marie; Johansson, Kjell Arne (Peer reviewed; Journal article, 2019-11-08)
      Background: A large proportion of people who inject drugs (PWID) living with hepatitis C virus (HCV) infection have not been treated. It is unknown whether inclusion of HCV diagnostics and treatment into integrated substance ...